Mizuho Securities analyst Vamil Divan maintained a Hold rating on SAGE Therapeutics (NASDAQ:SAGE) on Friday, setting a price target of $53, which is approximately 2.30% below the present share price of $54.25.
Divan expects SAGE Therapeutics to post earnings per share (EPS) of -$2.44 for the third quarter of 2020.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in SAGE Therapeutics, with an average price target of $68.36.
The analysts price targets range from a high of $87 to a low of $40.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $2.29 million and a net profit of -$131.62 million. The company’s market cap is $2.82 billion.
According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.3% and a 40.51% success rate.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.